Skip to content

A study comparing Haritkyadi Kwatha and Gokshura Kwatha in patients with painful and burning urination (Cystitis).

A Comparative Clinical Study t of Haritkyadi Kwatha and Gokshura Kwatha in the Management of Pittaja Mutrakruchha (Cystitis). - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/091986
Enrollment
70
Registered
2025-07-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N309- Cystitis, unspecified

Interventions

None listed

Sponsors

Pavan Suresh Ingle
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed patients of Mutrakruchha according to classical sign & symptoms H/o- Urinary Tract Infection not more than 7 days & didn t taken any antibiotics Age between 21-40 yrs Either Sex Dukhen Mutrapravritti Mutra Daha Pit varn mutra pravritti Swalpa Muhurmuhu Mutra pravritti

Exclusion criteria

Exclusion criteria: 1. Congenital Anomalies 2. K/C/O: BPH / Cancer / T.B / DM / HTN / STD / Impaired Renal Function and any other systemic disease 3. Renal Calculi, Pyelonephritis 4. Pregnant and Lactating Woman 5. Ashmarijanya, Shukrajanya, Purishaj and Shalyaj MutrakrMutrakruchha 6. Patient above 40 years and below 16 years 7. Any Comorbid condition

Design outcomes

Primary

MeasureTime frame
Efficacy of Haritkyadi Kwatha vs Gokshura Kwatha in reducing key symptoms of Pittaja Mutrakruchha (Cystitis) over a period of 28 days, assessed both subjectively and objectively. Subjective parameters: Burning micturition (Daha) Painful urination (Ruja) Frequency of micturition (Muhur Muhu Mutrata) Discoloration of urine (Mutra Varna) Objective parameters: Pus cells count in urine Epithelial cells Urinary albumin Urinary pH RBCs in urineTimepoint: Weekly upto 28 days

Secondary

MeasureTime frame
Overall symptom relief grading Excellent greater than 75 percent relief Marked 41 to 75 percent Moderate 25 to 50 percent Mild less than 25 percent Safety and tolerability Any adverse effect or withdrawal due to sideeffects Comparative effectiveness to determine which formulation is more effective clinically and objectivelyTimepoint: Weekly upto 28 days

Countries

India

Contacts

Public ContactDr Vishal Tamhane

Ashvin Rural Ayurved College and Hospital, Sadhvi Preetisudhaji Maharaj Nagar, Manchi Hill, Ashvi Bk, Tal. Sangamner, Dist. Ahmadnagar

vtamhane@gmail.com9764139607

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026